CRISPR Therapeutics AG (NASDAQ:CRSP) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twenty-two analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $74.40.

Several research firms have recently commented on CRSP. Barclays increased their price objective on CRISPR Therapeutics from $55.00 to $56.00 and gave the company an "equal weight" rating in a report on Wednesday, February 12th. Cantor Fitzgerald restated a "neutral" rating on shares of CRISPR Therapeutics in a research note on Wednesday. HC Wainwright restated a "buy" rating and issued a $65.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Needham & Company LLC reiterated a "buy" rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada lowered their price objective on CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating on the stock in a research report on Wednesday, February 12th.

Insider Activity

In other news, CEO Samarth Kulkarni sold 15,000 shares of CRISPR Therapeutics stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares in the company, valued at approximately $10,002,854. This trade represents a 7.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.10% of the company's stock.

Hedge Funds Weigh In On CRISPR Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. ARK Investment Management LLC increased its stake in shares of CRISPR Therapeutics by 19.7% in the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company's stock valued at $353,180,000 after purchasing an additional 1,474,439 shares during the last quarter. Capital International Investors increased its stake in shares of CRISPR Therapeutics by 10.3% in the 4th quarter. Capital International Investors now owns 8,743,523 shares of the company's stock valued at $344,145,000 after purchasing an additional 816,789 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its stake in shares of CRISPR Therapeutics by 39.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company's stock valued at $150,029,000 after purchasing an additional 1,074,238 shares during the last quarter. State Street Corp boosted its holdings in shares of CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company's stock valued at $140,611,000 after acquiring an additional 599,304 shares in the last quarter. Finally, FMR LLC boosted its holdings in shares of CRISPR Therapeutics by 1.0% during the 3rd quarter. FMR LLC now owns 2,376,166 shares of the company's stock valued at $111,632,000 after acquiring an additional 23,075 shares in the last quarter. Institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP traded down $2.52 during trading hours on Friday, reaching $47.91. 2,671,174 shares of the stock were exchanged, compared to its average volume of 2,550,435. CRISPR Therapeutics has a twelve month low of $36.52 and a twelve month high of $91.10. The firm has a 50 day moving average of $42.25 and a 200 day moving average of $46.04. The stock has a market cap of $4.11 billion, a PE ratio of -10.96 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. Equities research analysts anticipate that CRISPR Therapeutics will post -5.16 earnings per share for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.